Bayers, Asundexian

Bayer's Asundexian Approval Meets a Harder Question: Will It Move the Pharma Top Line?

Published on 11/20/2026 at 09:51 | Editorial boerse-global.de
Berenberg lifts Bayer target to EUR 62, Jefferies holds at EUR 48.50. Both say Hold — next revenue report may decide which target wins.
Bayers, Asundexian, Approval, Meets, Harder, Question, Move, Pharma, Top, Line Illustration mit AI erstellt.

Two analysts, one rating, and a EUR 13.50 spread between their targets. That is the unusual situation facing Bayer investors after a busy week of London conferences and revised models — and it explains why the stock's next revenue report may matter more than any single product headline.

Berenberg lifted its price target on Wednesday to EUR 62.00 from EUR 53.50, keeping its "Hold" rating. Jefferies, fresh from hosting its own pharma conference in London, reaffirmed "Hold" with a EUR 48.50 target on Thursday. The shares closed Thursday at EUR 54.46, down 2.3% on a weak day for German equities — placing the price almost exactly midway between the two objectives. One target implies upside; the other implies downside. The shared rating, on its own, tells investors very little.

What the Approval Does and Doesn't Prove

Last week the US Food and Drug Administration cleared Asundexian to reduce the risk of further strokes in certain adults. According to Bayer, it is the world's first approved factor XIa inhibitor. That is a genuine milestone for the compound. What it is not is evidence of commercial scale. A green light from regulators says nothing about how much revenue the drug will eventually generate — and that distinction sits at the heart of the gap between the two analyst camps.

Jefferies's Michael Leuchten acknowledged that Bayer now sees clearer signs of growth in its pharmaceuticals division. That was not enough to justify a higher valuation in his model. Berenberg, by contrast, has chosen to price in more of the upside without abandoning its cautious stance.

Should investors sell immediately? Or is it worth buying Bayer?

Guidance Is Not the Same as Delivery

Bayer has raised its outlook for the pharma margin, for group EBITDA before special items, and for free cash flow. The operative word is "outlook." A brighter forecast is not proof of higher profitability. In the third quarter of 2026, Bayer reported group revenue of EUR 10.053 billion and EBITDA before special items of EUR 1.615 billion. Whether an improved pharma margin can lift the adjusted result for the whole group is the question that will decide which target the market gravitates toward.

The bull case rests on a simple chain: Asundexian finds demand in its approved indication, contributes visibly to the pharma business, and — crucially — that contribution shows up at the divisional level rather than merely at the product level. New revenue that only offsets weakness elsewhere would leave Bayer with a scientific win and no aggregate growth. Conversely, a soft divisional top line would not, by itself, prove that Asundexian is selling poorly.

The Next Print Is the Real Arbiter

For that reason, the coming revenue disclosure carries more weight than the distance between the share price and any analyst target. Investors should watch not only the direction of pharma sales but also whether management explains which products are driving the number and whether Asundexian is already making a measurable contribution.

If the growth signals hold and Bayer can underpin them with divisional revenue, the scenario behind the higher target gains operational substance. If the pharma margin misses the upgraded expectations, the question shifts to whether the improved group earnings guidance can survive — and the lower target carries the day. Either way, the approval is settled. Its economic weight is not.

Ad

Bayer Stock: New Analysis - 20 November

Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Bayer analysis...

Disclaimer...
en | DE000BAY0017 | BAYERS | boerse | 70539382 |